SEC Form 4 · accession 0001387131-17-000665
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis J Carlo Ph.D.
Officer — President & CEO · Director
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 4:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.15 | Feb 7, 2017 | A | 477,000 | A | — | Feb 7, 2027 | Common Stock | 477,000 | 477,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the grant date.